Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company will be held on Tuesday October 31 2023 inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30 2023. Further in continuation of our earlier letter dated September 27 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for trading in the securities of the Company shall remain closed till November 02 2023.The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
